Keng Lam1, Abel Wu1. 1. Department of Neurology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, CA.
Abstract
INTRODUCTION: Nusinersen is an antisense oligonucleotide drug that was developed for treatment of spinal muscular atrophy (SMA). Its effectiveness for adults is limited; therefore, more clinical data are needed to guide adult SMA patients who are considering this treatment. METHODS: Through case series review, we retrospectively reviewed charts of Kaiser Permanente Southern California members who were already receiving nusinersen treatment, which has been available since August 2017. Patients were evaluated by physical therapy using the Hammersmith Functional Motor Scale (out of highest possible score of 40). RESULTS: We identified 4 adult patients who met our study criteria as of February 1, 2020. All patients were mobility device dependent. Patient age ranged from 23 to 56 years. A generalized linear model was used to assess trendlines for repeated measures within subjects. In this small sample, there appears to a significant increase in scores on repeated measures (p = 0.0027). CONCLUSION: Based on this small study, some adult SMA patients may benefit from treatment with nusinersen.
INTRODUCTION: Nusinersen is an antisense oligonucleotide drug that was developed for treatment of spinal muscular atrophy (SMA). Its effectiveness for adults is limited; therefore, more clinical data are needed to guide adult SMA patients who are considering this treatment. METHODS: Through case series review, we retrospectively reviewed charts of Kaiser Permanente Southern California members who were already receiving nusinersen treatment, which has been available since August 2017. Patients were evaluated by physical therapy using the Hammersmith Functional Motor Scale (out of highest possible score of 40). RESULTS: We identified 4 adult patients who met our study criteria as of February 1, 2020. All patients were mobility device dependent. Patient age ranged from 23 to 56 years. A generalized linear model was used to assess trendlines for repeated measures within subjects. In this small sample, there appears to a significant increase in scores on repeated measures (p = 0.0027). CONCLUSION: Based on this small study, some adult SMA patients may benefit from treatment with nusinersen.
Authors: Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo Journal: N Engl J Med Date: 2017-11-02 Impact factor: 91.245
Authors: Tim Hagenacker; Claudia D Wurster; René Günther; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Markus Weiler; Andreas Ziegler; Josua Kuttler; Jan C Koch; Ilka Schneider; Gilbert Wunderlich; Natalie Schloss; Helmar C Lehmann; Isabell Cordts; Marcus Deschauer; Paul Lingor; Christoph Kamm; Benjamin Stolte; Lena Pietruck; Andreas Totzeck; Kathrin Kizina; Christoph Mönninghoff; Otgonzul von Velsen; Claudia Ose; Heinz Reichmann; Michael Forsting; Astrid Pechmann; Janbernd Kirschner; Albert C Ludolph; Andreas Hermann; Christoph Kleinschnitz Journal: Lancet Neurol Date: 2020-03-18 Impact factor: 44.182
Authors: Basil T Darras; Claudia A Chiriboga; Susan T Iannaccone; Kathryn J Swoboda; Jacqueline Montes; Laurence Mignon; Shuting Xia; C Frank Bennett; Kathie M Bishop; Jeremy M Shefner; Allison M Green; Peng Sun; Ishir Bhan; Sarah Gheuens; Eugene Schneider; Wildon Farwell; Darryl C De Vivo Journal: Neurology Date: 2019-04-24 Impact factor: 9.910
Authors: Elisabeth Jochmann; Robert Steinbach; Thomas Jochmann; Ha-Yeun Chung; Annekathrin Rödiger; Rotraud Neumann; Thomas E Mayer; Klaus Kirchhof; Dana Loudovici-Krug; Ulrich C Smolenski; Otto W Witte; Julian Grosskreutz Journal: Ther Adv Neurol Disord Date: 2020-03-05 Impact factor: 6.570